Having trouble accessing articles? Reset your cache.

IQWiG rebuffs Dificlir, Picato

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said on Monday that two drugs offer "no additional benefit" over

Read the full 207 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE